Gilead Reports Updated Results of Descovy in P-III DISCOVER Study for Pre-Exposure Prophylaxis of H
Shots:
- The P-III DISCOVER study involves assessing of Descovy (emtricitabine- 200 mg/tenofovir alafenamide- 25 mg- qd) vs Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in adult male and transgender female with HIV PrEP
- The P-III DISCOVER study results: met its 1EPs of non-inferiority- reduction in time to achieve EC90 of tenofovir diphosphate (TFV-DP) in PBMCs- @4wks. TFV-DP level (98% vs 68%). Additionally- pharmacokinetic data showed Descovy maintains TFV-DP conc. level for a longer time than Truvada
- Descovy is a dual regimen therapy indicated in combination with other ARV for HIV-1 infections in patients weighing at least 35 kg
Click here to read full press release/ article
Ref: Gilead | Image: Gilead
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com